NCT03202940 is a Phase 1, PHASE2 clinical trial of Alectinib in Non-small Cell Lung Cancer, sponsored by Massachusetts General Hospital.

Who is sponsoring NCT03202940?

NCT03202940 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT03202940?

Interventions in NCT03202940: Alectinib, Cobimetinib.

What condition does NCT03202940 study?

NCT03202940 studies Non-small Cell Lung Cancer.

Is NCT03202940 still recruiting?

NCT03202940 is currently active, enrolled. Last updated 25 September 2025.

Last reviewed 2025-09-25 · How we verify

NCT03202940

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

Active, enrolled Phase 1, PHASE2 Last updated 25 September 2025

What this trial tests

Phase 1, PHASE2 trial testing Alectinib in Non-small Cell Lung Cancer in 16 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

14 September 2017

Primary endpoint
1 January 2029

1 January 2031

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	Phase 1, PHASE2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	14 September 2017
Primary completion	1 January 2029
Estimated completion	1 January 2031
Sites	1 location across United States

Drugs / interventions tested

Alectinib — full drug profile →
Cobimetinib (cobimetinib) — full drug profile →

Conditions studied

Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →

Sponsor

Massachusetts General Hospital

Who can join

18 and older, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study is studying a drug combination as a possible treatment for anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer. The drugs involved in this study are: * Alectinib * Cobimetinib

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.
Schram AM, Chang MT, Jonsson P, Drilon A. · · 2017 · cited 270× · PMID 28857077 · DOI 10.1038/nrclinonc.2017.127
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends.
Majeed U, Manochakian R, Zhao Y, Lou Y. · · 2021 · cited 193× · PMID 34238332 · DOI 10.1186/s13045-021-01121-2
ALK-positive lung cancer: a moving target.
Schneider JL, Lin JJ, Shaw AT. · · 2023 · cited 131× · PMID 36797503 · DOI 10.1038/s43018-023-00515-0
The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.
Gristina V, La Mantia M, Iacono F, Galvano A, et al · · 2020 · cited 56× · PMID 33352844 · DOI 10.3390/ph13120474
Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non‑small cell lung cancer (Review).
Wang L, Wang W. · · 2021 · cited 42× · PMID 33200229 · DOI 10.3892/or.2020.7851
Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review.
Desai A, Lovly CM. · · 2023 · cited 32× · PMID 37057106 · DOI 10.21037/tlcr-22-708
Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies.
Ou X, Gao G, Habaz IA, Wang Y. · · 2024 · cited 30× · PMID 39184861 · DOI 10.1002/mco2.694
The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives.
Cognigni V, Pecci F, Lupi A, Pinterpe G, et al · · 2022 · cited 24× · PMID 36230686 · DOI 10.3390/cancers14194765

Verify or expand the search:

Other trials of Alectinib

Trials testing the same drug.

NCT07001384 — A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (AL · Phase 1 · recruiting
NCT06862869 — Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Ther · recruiting
NCT06692491 — Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · Phase 2 · not yet recruiting
NCT06624059 — A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Can · Phase 1, PHASE2 · active not recruiting
NCT06532149 — ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer · recruiting

Other recruiting trials for Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03202940 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 25 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03202940.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing